$CRL

Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.

Charles River Laboratories (CRL) launched Apollo Orchestrate, a digital platform to streamline GMP QC workflows in North America and Europe. The system integrates Apollo and LabWare LIMS for enhanced traceability. According to the company, the move supports its digitization efforts in Biologics Testing Solutions.

Charles River Laboratories (CRL) and Autolomous launched Apollo Orchestrate™, a digital laboratory execution system. It connects and digitizes lab workflows, enhancing efficiency and transparency. The system is deployed across North America and Europe for QC testing. CRL aims to modernize lab workflows, while Autolomous's autoloMATE platform enables digital integration and cost savings.

Vaxcyte (PCVX) +31% on positive Phase 3 trial data, $500M stock offering. InfuSystem (INFU) +2% with Q2 revenue $36.9M, FY26 growth 6-8%. Illumina (ILMN) +7% with Q2 revenue $1.59B, FY26 guidance $4.6B-$4.64B. Charles River (CRL) +7% with Q2 revenue $1B, FY26 EPS up $0.25. HeartFlow (HTFL) +5% with Q2 revenue $64.1M, net loss $15.7M.

Coleman Glenn (EVP & Chief Financial Officer) purchased 10 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $297.43 on 2026-09-30.

UBS initiated coverage of Charles River Laboratories (CRL) with a Buy rating and $357 price target, citing growth in the CRO industry. CRL's P/S ratio is 3.62, above its historical median, reflecting market expectations for future growth. The company has a GF Score of 72/100, with mixed financial strength and profitability. Insiders have sold $42.6M in shares over the past year, while institutional ownership remains stable.

Jefferies raised its price target for Charles River Laboratories (CRL) to $340 from $305, maintaining a Buy rating. The firm cited revenue growth expectations and cost efficiencies from the company's Create the Future initiative. CRL shares have surged 84% in six months and 97% in a year, trading near a 52-week high. Analysts from JPMorgan, TD Cowen, Mizuho, and Evercore ISI also updated their price targets and ratings, reflecting positive outlooks on the company's performance.

TD Cowen raised its price target for Charles River Laboratories (NYSE:CRL) to $325 from $300, citing 5-7% organic revenue growth and low double-digit EPS growth through 2030. The stock is near its 52-week high after a 102% gain over the past year. Analysts forecast $11.63 EPS for fiscal 2026, with the Discovery and Safety Assessment segment seen as a key growth driver. CRL recently reported Q2 2026 earnings and revenue above expectations, raising its full-year outlook.

Charles River Labs rose 5% after reaffirming fiscal 2026 guidance. Nebius gained 6% on Bank of America's revenue upgrade. Oracle fell 4% after a force majeure notice on a data center project. Bloom Energy dropped 6% alongside Oracle. Arm Holdings slid 6% after its CFO sold shares. GoDaddy climbed 3% on a takeover offer from Gen Digital. Darden Restaurants dipped 2% despite in-line earnings. MGM Resorts tumbled 10% after a withdrawn takeover bid. Meta Platforms advanced 3% on AI optimism.

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.